Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.

ABSTRACT:

Background

Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA. Prior studies have identified a prominent interferon signature in AA, which signals through JAK molecules.

Methods

A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome. In vivo, preclinical studies were conducted using the C3H/HeJ AA mouse model to assess the mechanism of clinical improvement by baricitinib.

Findings

The patient exhibited a striking improvement of his AA on baricitinib over several months. In vivo studies using the C3H/HeJ mouse model demonstrated a strong correla

SUBMITTER: Jabbari A 

PROVIDER: S-EPMC4486197 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature